3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
87
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Recurrence
16
Burkitt Lymphoma
13
Neoplasms
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Leukemia, Biphenotypic, Acute
7
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
6
Lung Neoplasms
6
Immunoglobulin Light-chain Amyloidosis
6
Neoplasms, Plasma Cell
5
Hodgkin Disease
5
Smoldering Multiple Myeloma
4
Leukemia
4
Carcinoma, Non-Small-Cell Lung
4
Waldenstrom Macroglobulinemia
3
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Neoplasm Metastasis
3
Nausea
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma
3
Brain Neoplasms
3
Renal Insufficiency
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell
2
Lymphoma, B-Cell
2
Leukemia, Plasma Cell
2
Interventions
enzalutamide
5
darolutamide
4
Docetaxel
3
Prednisone
2
olaparib
1
gedatolisib
1
fludrocortisone acetate
1
cabazitaxel
1
abiraterone
1
TVB-2640
1
Radiosurgery
1
Omeprazole
1
Dexamethasone
1
Androgen Antagonists
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Prostatic Neoplasms, Castration-Resistant
×
Dexamethasone
×
Clear all
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled